We come to you as a partner rather than a service provider and we guarantee:
Synthesis and physico-chemical characterization of different types of multifunctional nanostructures and development of new imaging strategies on nanostructures and various biological samples.
Development of target therapies, diagnostic and prognostic tools and assessment of clinically relevant biomarkers with role in new targeted therapies, early diagnosis or prognosis.
High-resolution mass spectrometry (HRMS) based biomarker discovery towards precision medicine by employing: targeted and untargeted proteomics and/or metabolomics.
Development of preclinical animal models (immunocompromised or transgenic mice), preclinical evaluation of novel drugs and therapeutic combinations, imaging techniques (IVIS, mRI).
Our highly trained and dedicated team who has completed or ongoing doctoral studies, conducts their own postdoctoral research projects and are involved in multiple multidisciplinary research projects coordinated by members of scientific community.
The In vivo Studies – Animal Facility Department provides the opportunity to use advanced animal models needed to implement preclinical research projects to develop targeted therapeutic strategies and minimally invasive diagnostic/prognostic methods.
The Department is unique at national level in terms of infrastructure and hosts state-of-the-art imaging equipment – MRI and IVIS for highly refined in vivo imaging investigations.
The laboratory animal housing space is also under strict sterility control to create an aseptic environment necessary for advanced animal models with severe immunocompromised or genetically modified phenotype.
The NanoBioPhysics Department has an interdisciplinary structure addressing highly topical scientific issues in biomedicine and biotechnology.
The department has state-of-the-art equipment allowing both the synthesis and fully physico-chemical characterisation of different types of hybrid multifunctional nanostructures (plasmonic, magnetic, magnetoplasmonic, liposomal, polymeric nanoparticles, carbon quantum dots, etc.) and the investigation at the nanoscale of their interactions with different molecules or biological environments.
The Proteomics and Metabolomics Department exploits advanced sample preparation workflow and high-resolution mass spectrometry (LC-QTOF-IMS, ICP-MS, GC-MS) to achieve protein and metabolites profiling of a wide range of specimens – serum, plasma, fresh frozen tissue, paraffin-embedded tissue (FFPE), cell culture lysates, a unique proteomic and metabolomic platform in Romania.
The Translational Medicine Department provides comprehensive experimental cell culture and in vitro functional assays, as well as molecular assays at the DNA, RNA and protein level.
Specifically, the department supports cell line expansion, cryopreservation for cell banking, in vitro testing of active compounds and evaluation of their efficacy through cytotoxicity assays, imaging evaluations and enzyme-linked immunosorbent assays.
Changes at the molecular level are quantified by PCR, RT-qPCR and Western Blot assays.
The Clinical Studies Support Department is the newest department in the center. It aims to contribute to the implementation of diagnostic and treatment strategies with potential major benefits in the clinical space, and on the other hand to provide an alternative source of funding for research activities.
The department has two laboratories:
The Hemostasis Laboratory
The Laboratory of Hemostasis, part of the Department of Support for Clinical Studies has a main purpose the diagnosis and monitoring of coagulation disorders, for patients from Cluj Napoca and Transylvania, having been established in collaboration with the Romanian Society of Hematology and initially financed by the international grant of the Novo Nordisk Foundation, from Zurich, Switzerland. The Laboratory of Hemostasis collaborated with the departments of hematology and pediatrics in the region, playing a role in diagnosing and monitoring patients with hemophilia and rare coagulation disorders.
MetaboMS Laboratory
MetaboMS Laboratory – was developed through a pilot program in collaboration with the Ministry of Health, being funded by the SEE and Norwegian Grants financed by Iceland, Lichtenstein and Norway. The activities carried out in this laboratory are part of preventive health care services and have as main objective the early identification of 32 inherited metabolic disorders.